Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $9.45

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given an average rating of “Moderate Buy” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $9.27.

Several research analysts have weighed in on HCAT shares. Canaccord Genuity Group cut their price objective on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Stifel Nicolaus decreased their price objective on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Citigroup reduced their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, Stephens dropped their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday.

Insiders Place Their Bets

In other news, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total value of $50,762.96. Following the completion of the transaction, the insider now owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. This represents a 6.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at $685,310.03. This represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,243 shares of company stock worth $273,620. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new position in shares of Health Catalyst in the 3rd quarter worth approximately $897,000. Fred Alger Management LLC bought a new position in Health Catalyst during the 3rd quarter valued at approximately $6,858,000. Millrace Asset Group Inc. bought a new position in Health Catalyst during the 3rd quarter valued at approximately $1,568,000. Point72 Asset Management L.P. increased its position in Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares in the last quarter. Finally, Impax Asset Management Group plc increased its position in Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after buying an additional 360,201 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Down 3.2 %

HCAT stock opened at $4.29 on Wednesday. The stock’s fifty day simple moving average is $5.73 and its two-hundred day simple moving average is $7.16. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 1-year low of $3.76 and a 1-year high of $9.24. The stock has a market cap of $301.21 million, a P/E ratio of -3.18 and a beta of 1.41.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.